Department of Molecular Oncology

Department head: Professor Ragnhild A. Lothe
Deputy department head: Professor Rolf I. Skotheim
Laboratory manager: Professor Guro E. Lind
Department administrative consultants: Mona Hagen and Linda Uv Mjøen

Research groups:

Genetics Genome Biology Epigenetics
Ragnhild A. Lothe
Rolf I. Skotheim
Guro E. Lind

Project groups in the Lothe lab:

Cell signalling  Computational Oncology  
Edward Leithe
Anita Sveen
 

As a research department within the OUH Comprehensive Cancer Centre, it is our responsibility and goal to accomplish high quality and interdisciplinary biomedical research for improved precision medicine and management of cancer patients.

About:

Our main research programs are devoted to colorectal cancer and prostate cancer (Link), and we have a longstanding project portfolio also on other solid tumor types. Our expertise in biomedical research spans several disciplines from cell biology to translational research, including also active clinical research collaborations, and we have a broad range of advanced technologies established in-lab (Link). The department scientists are inventors of several biomedical patents and active innovation projects.

Lothe lab – genetics, genomics, cell signaling, colorectal cancer, MPNST, tumor heterogeneity, pharmacogenomics, biomarkers

Skotheim lab – genome biology, transcript variation, tumor heterogeneity, prostate cancer, testicular cancer, bioinformatics

Lind lab – epigenetics, genetics, GI-cancers, bladder cancer, early detection, monitoring

Affiliations

All three group leaders are adjunct professors at the University of Oslo and are affiliated with the Institute for Clinical Medicine, the Institute for Biosciences and the Institute for Informatics. We aim to complete at least 3 academic degrees annually, and since the inauguration of the Department in 2006, 53 MSc/PhD degrees have successfully been defended (Link).

The research groups are partners of the K. G. Jebsen Colorectal Cancer Research Centre (led by Prof. Lothe), the OUH priority area for colorectal cancer, the Norwegian Cancer Genomics Consortium, the European network for study on Cholangiocarcinoma, and the Global Testicular Cancer Consortium.

The K.G. Jebsen Colorectal Cancer Research Centre.


Latest News

 

Popular science dissemination of cancer genomics

Research from the Department of Molecular Oncology has recently been profiled in three popular science articles.

In an interview in Apollon, Rolf Skotheim discusses why some healthy cells turn into cancer cells.

Bjarne Johannessen and Kaja C. G. Berg have written about colorectal cancer cell lines in the magazine BestPractice. BestPractice is a Norwegian medical journal which focuses on oncology and hematology.

In the same journal, Anita Sveen has written about tumor heterogeneity in metastatic colorectal cancer.

 

Preclinical drug screening identifies novel stratified treatment options according to the consensus molecular subtypes of colorectal cancer

From left: Anita Sveen, Jarle Bruun and Peter W. Eide.
From left: Anita Sveen, Jarle Bruun and Peter W. Eide.

In two recent publications (Eide PW et al. Sci Rep; Sveen A*, Bruun J* et al. Clin Cancer Res), scientists in the Lothe lab., Department of Molecular Oncology, have identified novel potential treatment strategies for colorectal cancer (CRC), guided by the consensus molecular subtypes (CMS). Combining algorithm development, for translation of CMS classification to preclinical models, with drug screening of classified cell lines and patient-derived xenografts (PDXs) in collaboration with the Finnish Institute for Molecular Medicine and Vall d´Hebron Institute of Oncology, a potential to overcome chemoresistance in the poor prognostic CMS4-mesenchymal group was identified by combination therapy with 5-fluorouracil (5-FU) and HSP90 inhibitors.

 

Dr. Jarle Bruun's research profiled in the 2016 National report from the Health Regional Authorities

08.08.2017

The report highlights clinically relevant research and projects ongoing in the KG Jebsen Colorectal cancer research centre was selected from the Health Region South East. Specifically, Dr Jarle Bruun's paper identifying the gene Regulator of chromosome condensation 2 (RCC2) as functionally important in colorectal cancer, and furthermore that changes of RCC2 at the DNA and protein level can identify clinically distinct subgroups of patients with inferior survival. This is the first paper that reports clinical relevance of RCC2 in cancer. Bruun has already contributed to two ongoing innovation projects from the Lothe group at the Department of Molecular Oncology, Institute for Cancer Research.

Forskning og innovasjon til pasientens beste - Nasjonal rapport fra spesialisthelsetjenesten 2016

 


Contact information

Department of Molecular Oncology, Institute for Cancer Research
Oslo University Hospital HE - Norwegian Radium Hospital
Mail address: P. O. Box 4953 Nydalen, NO-0424 Oslo, Norway
Street address: Norwegian Radium Hospital, Montebello
Phone: +47 2278 1728, Switchboard: +47 2293 4000, Fax: +47 2278 1745
E-mail: ragnhild.a.lothe@rr-research.no

 
Page visits: 11934